Drugs / Dichrostachys glomerata
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06827002 | Mar 2023 → Feb 2026 overdue | obesity disorder | University of Yaounde 1 | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dichrostachys glomerata | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06827002 ↗ |
| Action | Inhibit | “both DGE and CQE significantly increased GLP-1 levels and inhibited DPP-4 activity compared to the control group” NCT06827002 ↗ |
| Route | Oral | “will be administered 400mg DGE capsule daily for 16 weeks” NCT06827002 ↗ |